If efficiently and safely scaled up in DMD patients, this technique could lead to one of the first successful genome editing-based treatments for this fatal disease, researchers said.
DMD, the most common and severe form of muscular dystrophy among boys, is characterized by progressive muscle degeneration and weakness. It is caused by mutations in the X-linked DMD gene that encodes the protein dystrophin. The disease affects one in 3,500 to 5,000 boys, according to the Centers for Disease Control and Prevention and other estimates, and often leads to premature death by the early 30s.
Although the genetic cause of DMD has been known for nearly 30 years, no effective treatments exist. The disease breaks down muscle fibers and replaces them with fibrous or fatty tissue, causing the muscle to gradually weaken. This condition often results in heart muscle disease, or cardiomyopathy, the leading cause of death in these patients.
In the study published today in Science, UTSW researchers used a gene-editing approach to permanently correct the DMD mutation that causes the disease in young mice.
“This is different from other therapeutic approaches, because it eliminates the cause of the disease,” said senior author Dr. Eric Olson, Chairman of Molecular Biology, and Co-Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center at UT Southwestern.
In 2014, Dr. Olson’s team first used this technique – called CRISPR/Cas9-mediated genome editing – to correct the mutation in the germ line of mice and prevent muscular dystrophy. This paved the way for novel genome editing-based therapeutics in DMD. It also raised several challenges for clinical applications of gene editing. Since germ line editing is not feasible in humans, strategies would need to be developed to deliver gene-editing components to postnatal tissues.
To test this out, researchers delivered gene-editing components to the mice via adeno-associated virus 9 (AAV9). DMD mice treated with this technique produced dystrophin protein and progressively showed improved structure and function of skeletal muscle and heart.
“AAV9 can efficiently infect humans in a tissue-specific manner, but it does not cause human disease or toxicity. It’s a molecular missile for gene therapy,” said Dr. Leonela Amoasii, a postdoctoral researcher in the Olson lab and co-lead author of the study with Dr. Chengzu Long, Instructor of Molecular Biology.
“The CRISPR/Cas9 system is an adaptive immune system of single-celled organisms against invading virus. Ironically, this system was hijacked, we packaged it into a nonpathogenic virus, and corrected a genetic mutation in an animal model,” added Dr. Long.
The CRISPR genome-editing technology, which was developed by a researcher at University of California at Berkeley, was picked as the “Breakthrough of the Year” scientific development by Science.
“This study represents a very important translational application of genome editing of DMD mutations in young mice. It’s a solid step toward a practical cure for DMD,” said Dr. Rhonda Bassel-Duby, Professor of Molecular Biology and Co-Principal Investigator of a genomic editing project with Dr. Olson at the Wellstone Center.
“Importantly, in principle, the same strategy can be applied to numerous types of mutations within the human DMD patients,” added Dr. Olson, who also serves as Director of the Hamon Center for Regenerative Science and Medicine, and holds the Annie and Willie Nelson Professorship in Stem Cell Research, the Pogue Distinguished Chair in Research on Cardiac Birth Defects, and the Robert A. Welch Distinguished Chair in Science.
Now, the research team is working to apply this gene-editing technique to cells from DMD patients and in larger preclinical animal models.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseaseson August 5, 2021 at 4:48 am
Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseasesBOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) ...
- Stealth BioTherapeutics Reports Second Quarter 2021 Financial Results And Recent Business Highlightson August 5, 2021 at 4:30 am
Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial ...
- PepGen raises $113M to challenge Sarepta in DMD, build neuromuscular and neurologic pipelineon August 5, 2021 at 4:00 am
Earlier this year, Sarepta linked its cell-penetrating peptide asset SRP-5051 to mean dystrophin production of 6.55% of normal, compared to 0.82% for Exondys 51, in DMD patients. McArthur has his ...
- Sarepta Therapeutics (SRPT) Q2 2021 Earnings Call Transcripton August 5, 2021 at 1:01 am
Q2 2021 Earnings CallAug 04, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, ladies and gentlemen, and welcome to the ...
- Sarepta adds another gene therapy to its ever-expanding pipelineon August 4, 2021 at 8:42 am
The biotech company followed through on an option deal it struck two years ago with Nationwide Children's, licensing an experimental treatment for the most common form of limb-girdle muscular ...
- Duchenne Muscular Dystrophy Market Will Hit Big Incomes in Near Future, Key Players – PTC Therapeutics, pSarepta Therapeutics, Others.on August 4, 2021 at 6:27 am
The Duchenne Muscular Dystrophy Market is expected to grow at a CAGR of 7.12% and is poised to reach $XX Billion by 2027 as compared to $XX Billion in 2020. The factors leading to this extraordinary ...
- Patients to the fronton July 30, 2021 at 2:00 am
In 2013, Annie and Ilan Ganot co-founded Solid Biosciences, with Ilan at the helm as president and CEO and Annie as head of patient advocacy. The company’s namesake is their son: Eytani is Hebrew for ...
- Screening for Duchenne muscular dystrophy now available for all babies born at the Brighamon July 29, 2021 at 5:00 pm
Brigham and Women’s Hospital will now offer an optional screening test for all babies born at the hospital for a disorder known as Duchenne Muscular Dystrophy (Duchenne).
- Global Duchenne Muscular Dystrophy Drugs Market Size, Status and Forecast 2021-2027on July 29, 2021 at 1:28 am
Pages Report] Check for Discount on Global Duchenne Muscular Dystrophy Drugs Market Size, Status and Forecast 2021-2027 report by QYResearch Group. Market Analysis and Insights: Global Duchenne ...
- Global Duchenne Muscular Dystrophy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027on July 29, 2021 at 1:28 am
Pages Report] Check for Discount on Global Duchenne Muscular Dystrophy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027 report by QYResearch Group. uchenne muscular ...
via Bing News